Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05189977
Other study ID # 331-201-00246
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date September 7, 2022
Est. completion date August 3, 2023

Study information

Verified date January 2024
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline


Recruitment information / eligibility

Status Terminated
Enrollment 34
Est. completion date August 3, 2023
Est. primary completion date August 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Primary Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition criteria Diagnosis of Major Depressive Disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, social anxiety disorder or obsessive-compulsive disorder - Must be able to receive a sertraline dose of 150 mg/day by the second screening visit (Day -15) Exclusion Criteria - Sexually active males or females, who could become pregnant, not agreeing to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days at the end of the study - Diagnosed hypertension (including treated or untreated hypertension), or orthostatic hypotension - Epilepsy or a history of seizures - History of neuroleptic malignant syndrome or serotonin syndrome. - Primary DSM-5 diagnosis of Schizophrenia spectrum and other psychotic disorders, Bipolar and related disorders, Feeding and eating disorders (including anorexia nervosa or bulimia), Neurocognitive disorders (including but not limited to delirium, major or mild neurocognitive disorder due to Alzheimer's, Parkinson's, or traumatic brain injury) - A significant risk of committing violent acts, serious self-harm, or suicide - History of diabetes mellitus (type 1 or type 2) - Subjects with any previous exposure to brexpiprazole, or subjects with chronic use of prazosin or propranolol in the 90 days prior to the screening visit or any use in the 21 days (3 weeks) prior to the screening visit.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Propranolol
Propranolol (tablet, oral ): 40 mg QD Day 3 and Day 21 Intervention 1 is a single dose of prazosin administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state.
Prazosin
Prazosin (tablet, oral): 1 mg QD Day 2 and Day 20 Intervention 2 is a single dose of propranolol administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state.

Locations

Country Name City State
United States For additional information regarding sites (California, Texas, New Jersey, Minnesota) Princeton New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc. Iqvia Pty Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes between the control and treatment periods on Day 19 vs. Day 1, Day 20 vs. Day 2, and Day 21 vs. Day 3, with prazosin or propanolol in the presence of brexpiprazole + sertraline or sertraline alone at steady state Mean difference in baseline-adjusted change in systolic blood pressure (??SBP), measured in mmHg, from supine to standing positions will be assessed. 21 days
Primary Maximum change in SBP, measured in mmHg, from supine to standing position in the presence of brexpiprazole + sertraline or sertraline alone at steady state will be assessed. 21 days
Primary Maximum change in diastolic blood pressure (DBP), measured in mmHg, from supine to standing position in the presence of brexpiprazole + sertraline or sertraline alone at steady state will be assessed. 21 days
Primary Maximum change in resting heart rate (HR), measured in beats per minute (bpm), from supine to standing position will be assessed in the presence of brexpiprazole + sertraline or sertraline alone at steady state will be assessed. 21 days
See also
  Status Clinical Trial Phase
Completed NCT01806168 - rTMS in the Treatment of PTSD N/A
Not yet recruiting NCT06194851 - Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD Phase 2
Completed NCT02187224 - Progesterone Effect on Individuals Diagnoses With AD and PTSD. Phase 2/Phase 3
Completed NCT02549508 - Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD N/A
Not yet recruiting NCT01940549 - Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder N/A
Completed NCT02012738 - Treatment of Trauma and Violence in the Townships of South Africa N/A
Not yet recruiting NCT06419959 - NightWare and Cardiovascular Health in Veterans With PTSD N/A
Terminated NCT03209882 - Transcranial Infrared Laser Stimulation (TILS) of Prefrontal Cognition in Post-traumatic Stress Disorder (PTSD) N/A
Completed NCT04891614 - The PRISM Pilot Trial for Post-Traumatic Stress Disorder N/A
Recruiting NCT05407337 - The Effect of Narrative Exposure Therapy Intervention on Post-traumatic Stress Dissorder and Personal Recovery in Refugees and Asylum Seekers of Sindiane Programme N/A
Completed NCT02030522 - Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma N/A
Completed NCT01729325 - Prevention of Post-Traumatic Stress Disorder in Soldiers Phase 2
Completed NCT02053532 - Functional Brain Imaging in PTSD N/A
Not yet recruiting NCT02598024 - Treating Earthquake in Nepal Trauma (TENT) Trial 2016 N/A
Terminated NCT02237703 - Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD) N/A
Withdrawn NCT02356861 - LED Light Therapy to Improve Cognitive & Psychosocial Function in TBI-PTSD Veterans N/A
Not yet recruiting NCT05974631 - Evaluating Treatments for Suicidal Veterans With PTSD N/A
Not yet recruiting NCT06288594 - TraumaRelief App: A Pilot RCT Assessing Feasibility and Acceptability N/A
Completed NCT01847469 - Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence Phase 2
Terminated NCT02237677 - CB1 Receptor PET Imaging Reveals Gender Differences in PTSD N/A